Exabis Library
Welcome to the e-CCO Library!
P632: Allogenic hPDMSCs gelatum in the treatment of perianal fistulas in patients with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P632: Comparative analysis of the pharmacokinetics of Inflectra® biosimilar with Remicade® in the induction phase of remission in patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P632: Estimating indirect and out-of-pocket disease-associated costs in paediatric Inflammatory Bowel Disease: a nation-wide cross-sectional analysis
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P632: Etrasimod induction therapy in moderately to severely active Crohn's disease: results from a phase 2, randomised, double-blind substudy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P632: Is the gender or age of the physician key to a good physician-patient with Inflammatory Bowel Disease relationship?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P632: Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P633 Sustained reduction of IL-23-related cytokines IL-17A and IL-22 in a phase 2 study of mirikizumab in the treatment of patients with moderately-to-severely active ulcerative colitis through week 52
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P633: Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P633: Choice of first biologic in moderate to severe ulcerative colitis – a decision analysis using time-on-treatment and UK costs
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P633: Clinical epidemiology of Inflammatory Bowel Disease in Lbanon
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P633: Concordance between endoscopy and histology scores at baseline and following induction therapy with the JAK1 inhibitor filgotinib in active Crohn’s disease: Results from FITZROY study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P633: Harmonisation of quality of care in an IBD centre impacts disease outcomes: importance of structure and process indicators
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P634 Predictors of response and course in patients with inflammatory bowel disease treated with biological therapy: The Danish IBD-Biobank project
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P634: Clinical and endoscopic remission with vedolizumab treatment in ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P634: Long term risk of relapse after anti-TNF discontinuation based on mucosal healing in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P634: Real-world data on the efficacy and safety of vedolizumab therapy in patients with inflammatory bowel disease: a retrospective nation-wide cohort study in Singapore
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P634: Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P634: Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM